Chinese Hamster Ovary (CHO) cells are the preferred host for producing biotherapeutics where cell line development (CLD) is the foundation of the bioprocess. CLD processes are expected to be robust while meeting a myriad of regulatory requirements. The choice of the production cell line, culture conditions, and having a chemically defined (CD) CLD process by using CD cloning media can impact the subsequent measures for the CMC (chemistry, manufacturing, and controls). In this presentation, we will discuss these choices and their impacts on subsequent bioprocess and CMC testing required by regulations and the benefits of incorporating CD cloning media into the CHOZN® expression platform.
In this webinar, you will learn about:
<ul>
<li>Risk assessment approaches in upstream process development</li>
<li>How early cell line development stage is linked to subsequent steps in the bioprocess to assure the quality of the final product</li>
<li>Benefits of having a completely chemically defined cell line development process</li>
</ul>

aem-GridColumn aem-GridColumn--default--9

<h2 class="webinar-subtitle">WEBINAR</h2>

aem-GridColumn aem-GridColumn--default--9 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

aem-GridColumn aem-GridColumn--default--3 aem-GridColumn--offset--default--0 aem-GridColumn--default--none

Production choices impact bioprocess and CMC testing, discussed with CD cloning media.

Risk Mitigation in Cell Line Development

WEBINAR